Science is exploring new avenues to understand the scope of next-generation medications, such as those based on GLP-1 receptor agonists (the Ozempic family). Beyond their primary use for diabetes and obesity, recent studies suggest these drugs could influence brain circuits related to reward, impulsivity, and decision-making.
A study published in the scientific journal Criminology by Rutgers University analyzed data from over 7,500 adults in the United States. The findings indicated that individuals taking medications like Ozempic or Wegovy for weight loss showed a significant reduction in violent and impulsive behaviors. Specifically, the association between impulsivity and violence was 62% weaker, and the link between alcohol consumption and violence decreased by 52% in this group.
Researchers propose that GLP-1 agonists might modulate the brain's reward systems and impulse control circuits. This would not eliminate impulsivity itself but would weaken the jump from initial impulse to final action, functioning similarly to cognitive-behavioral therapy.
“"These medications could function as a cognitive-behavioral therapy focused on weakening the path from impulse to action rather than eliminating impulsivity itself."
Lead author Christopher Thomas and co-author Daniel C. Semenza from Rutgers University emphasize the importance of continued research into these behavioral effects as these medications become more widespread, considering it a public health issue.
Previous studies had already suggested benefits in reducing addiction risk. GLP-1 drugs may decrease the "value" the brain assigns to addictive substances, thereby reducing cravings and the likelihood of relapse or escalating use. Some research has linked their use to lower rates of overdose, drug-related hospitalizations, and even substance use mortality, in addition to potential reductions in alcohol, opioid, or nicotine use disorders.
